Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  by Proesmans, M. et al.
Journal of Cystic Fibrosis 12 (2013) 29–34
www.elsevier.com/locate/jcfOriginal Article
Comparison of two treatment regimens for eradication of Pseudomonas
aeruginosa infection in children with cystic ﬁbrosis
M. Proesmans a,⁎, F. Vermeulen a, L. Boulanger a, J. Verhaegen b, K. De Boeck a
a Department of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
b Department of Microbiology, University Hospital of Leuven, Leuven, Belgium
Received 24 January 2012; received in revised form 24 May 2012; accepted 1 June 2012
Available online 2 July 2012Abstract
In patients with cystic ﬁbrosis (CF), treatment of new Pseudomonas aeruginosa (Pa) infection postpones the occurrence of chronic infection,
but the best eradication regimen is unknown .
Aim of the study: Compare 2 Pa eradication regimens in children with new Pa infection.
Methods: Children with CF (0–18 years) and a new isolation of Pa from sputum, cough swab or BAL were randomized to treatment with
tobramycin inhalation solution for 28 days (TIS) or inhaled sodiumcolistimethate (2×2 mill U/day) plus oral ciproﬂoxacin (30 mg/kg/day) for
3 months (CC). Airway cultures were taken for 6 consecutive months, then every 3 months. The primary outcome was Pa eradication at the end of
treatment. Secondary outcome parameters were: time to Pa relapse from end of treatment, total and Pa speciﬁc IgG, FEV1, BMI and Pa status at
2 year follow-up.
Results: 58 patients with new Pa isolation were randomized. Their median age was 9 years (IQR 4.7–13.1) and their median FEV1 98% predicted
(IQR 87–107). Eighteen treatments concerned the ﬁrst Pa isolation ‘ever’ (TIS: 8; CC: 10). For the remaining, median time since previous Pa was
19 months (IQR 9–41). Eradication at end of treatment was similar for both treatments: 26/29 CC and 23/29 in TOBI treated patients (p=0.47).
Median time to recurrence of Pa was 9 months (95% CI 0.0–19.0) for CC and 5 months (95% CI 1.7–8.3) for TIS (p=0.608). After 1 year, the 2
groups did not differ in change in total and Pa speciﬁc IgG, FEV1 and BMI. After 2 years, 10% of patients had chronic Pa infection.
Conclusion: In children with CF and new Pa infection, inhalation of TIS (28 days) or CC (3 months) resulted in similar eradication success at the
end of treatment (80 and 90% respectively) and similar clinical evolution during the ﬁrst 2 years of follow-up.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pseudomonas aeruginosa; Lung infection; Eradication1. Introduction
In children with cystic fibrosis (CF),Pseudomonas aeruginosa
(Pa) lung infection is associated with increased morbidity and
mortality [1–3]. Especially chronic Pa lung infection and/or
conversion to a mucoid Pa phenotype are associated with more
rapid decline in lung function [3].⁎ Corresponding author at: University Hospital of Leuven, Dept Pediatrics,
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doi:10.1016/j.jcf.2012.06.001Intermittent Pa colonization nearly always precedes chronic
infection, and this window of opportunity can be utilized to
eradicate Pa from the respiratory tract. Because the combination
of inhaled colistin plus oral ciprofloxacin was the first treatment
regimen proven to postpone chronic Pa infection [4,5], this
treatment is still commonly used across Europe [6]. In recent
years, other antibiotic eradication therapies for new or early Pa
infection have been evaluated [7,8], and diverse treatments are
currently used. In Europe, the most common approach for
eradicating Pa infection continues to be nebulized colistin in
conjunction with oral ciprofloxacin (43%), closely followed by
nebulized tobramycin (41%) [6].by Elsevier B.V. All rights reserved.
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varies from 25 to 100% with a median time to relapse of Pa
infection from 8 to 18 months [4,5,7,9–15] . Treatment with
oral ciprofloxacin and inhaled sodiumcolistimethate (both for a
period of 3 months) protected 80% of children from chronic Pa
infection up to age 15 years [5]. Using this same eradication
protocol, variable eradication success and times to relapse were
reported in other retrospective or non-randomized studies [16].
Inhaled tobramycin monotherapy has also proven effective in
eradicating early Pa infection [7]. In recent studies the high
dose formulation of tobramycin for inhalation (TIS) is used.
TIS administered twice daily for 28 days was superior to
placebo [15], but in the ELITE trial, TIS treatment for 56 days
was not superior to TIS treatment for 28 days [7]. In the EPIC
trial, TIS was used as monotherapy or combined with oral
ciprofloxacin either as a cycled therapy or whenever Pa was
cultured from the respiratory secretions [8]. The addition of
ciprofloxacin and prophylactic cycles of treatment was not
more effective than TIS monotherapy or TIS at time of new Pa
infection only.
Since comparative data for TIS versus inhaled colistin plus
oral ciprofloxacin (CC) are not available, we conducted a
monocentric prospective randomized open label trial comparing
CC with inhaled TIS monotherapy for the eradication of new Pa
infection in a real life clinical setting.
2. Patients and methods
2.1. Study design
This is a single center open label prospective randomized
trial. During the time of the study (August 2004–August 2010)
all pediatric patients with first Pa infection ever or new Pa
infection after at a Pa free period of at least 6 months were
assessed for participation.
Inclusion criteria were: 1. diagnosis of CF (clinical signs
consistent with CF and a sweat chlorideN60 mEq/l by quantita-
tive pilocarpine iontophoresis and/or two CF causing mutations
identified), 2. age 0 to 18 years at time of inclusion, 3. First or
new Pa infection was defined as the first Pa isolation ever or
isolation of Pa from the airway (sputum, throat swab or BAL)
after a Pa free interval of at least 6 months and documented with
at least 3 negative cultures.
Exclusion criteria were: 1. chronic Pa infection according
to the Leeds criteria [18], 2. pulmonary exacerbation needing
intravenous antibiotic (IV AB) treatment at the time of Pa
isolate, 3. Pa isolation at the time of CF diagnosis, 4. patient
already on antipseudomonal antibiotics and 5. interval between
positive culture and start of treatmentN4 weeks.
Patients were randomized 1:1 to oral ciprofloxacin (30 mg/
kg/day) combined with inhaled colistin (Colistineb® Forest
Laboratories, Kent UK) (2 mill units BID) (CC) for 3 months
or monotherapy with tobramycin inhalation solution (TIS)
(TOBI ® Novartis Pharma AG, Basel, Switzerland) 300 mg
bid for 28 days. Block randomization was used per 10 patients.
Study duration was 1 year with follow up for Pa status until
2 years after inclusion. Approval of the local ethical com-mittee was obtained and parental written informed consents
were used.
The primary outcome was Pa eradication at the end of the
treatment i.e. culture taken at 28 days (TIS) or 3 months (CC).
Secondary outcome parameters were time to new Pa positive
culture (=relapse; calculated from end of treatment) and Pa
eradication 6 months after study entry. Additionally, 1 year after
study entry, FEV1 % change from baseline, IgG (Nephelometry,
Beckman-Immage 800) z score change from baseline [19] and
BMI z score change from baseline were calculated. Pa antibodies
(ELISA St Ag 1–17) [19] were determined at 1 year and Pa
status was assessed 1 and 2 years after study entry and reported as
‘Free of Pa’, ‘Intermittent Pa infection’ or ‘Chronic Pa infection’
according to the Leeds criteria [18].
2.2. Patient management
Patients were examined in the outpatient clinic every
3 months and spirometry was performed in patients N5 years
of age. FVC and FEV1 were expressed as % predicted
according to Wang [20].
If the airway culture was still Pa positive at the end of the
treatment, patients were changed to the other treatment arm
(‘rescue treatment’). In case of Pa relapse within 6 months of
study entry, patients were started on CC for 3 months or received
IV antipseudomonal antibiotics if clinically indicated. If during
the first 6 months, administration of additional antibiotics (oral,
inhaled or IV) was clinically indicated (without Pa relapse) this
was registered as ‘additional symptomatic treatment’. In case of
medication intolerance, the patient was changed to the other
treatment arm (but analyzed in the original randomization arm).
2.3. Airway cultures
After study entry, airway cultures were performed monthly for
6 months, then every 3 months. Sputa, cough swabs and bronchus
aspirates were inoculated on Columbia Agar Base (CMO331;
Oxoid, Basingstoke, UK) with 5% defibrinated horse blood,
MacConkey agar (CM0007; Oxoid),Mannitol Salt agar (CM0085;
Oxoid) and Burkholderia cepacia Medium (MAST DM253 D+
SV22). MacConkey agar and Mannitol Salt agar were aerobically
incubated at 37 °C for 48 h, Columbia Blood agar in 5% CO2 at
37 °C for 48 h and Burkholderia cepacia medium aerobically at
37 °C for 7 days. Different Pa phenotypes in each patient were
identified using a combination of conventional identification
methods (growth at 42 °C, positive oxidase, nitrate reduction and
arginine dehydrolase), as well as the Vitek 2 system (BioMérieux,
Marcy l'Etoile, France), cellular fatty acid analysis by gas
chromatography and since 2010 with mass spectrometry analysis.
The susceptibility of Pa isolates was determined by disc
diffusion (RoscoNeosensitabs) for mucoid strains and with
Vitek 2 system for other phenotypes.
2.4. Statistical analysis
Sample size calculations were based on previous data for Pa
eradication for CC (80%) [5] and TIS (between 74% and 90%)
Table 1
Baseline characteristics for both treatment groups.
CC n=29 TOBI n=29 p Value
Age (years) 10.8 (4.7–14.6) 8.8 (4.6–11.6) 0.556
Gender (M/F) 15/14 16/13 0.500
Weight z score −0.3 (−1.4 to −0.2) −0.5 (−1.0–0.15) 0.556
Length z score −0.8 (−1.5 to
−0.01)
−0.3 (−1.0 to
−0.05)
0.271
BMI 17.2 (15.8–18.2) 16.2 (14.6–18.5) 0.312
BMI z score −0.1 (−1.0 to −0.6) −0.4 (−1.0–0.4) 0.889
F508 del 0/1/2 1/9/19 3/13/13 0.240
PI/PS 27/2 29/0 0.491
FEV1% pred 98.0 (87.5–108.5) 97 .0 (85.8–106.3) 0.894
FVC % pred 104.0 (97–112.5) 99.0 (90.8–109.5) 0.298
First Pa ever y/n 10/19 8/21 0.777
Time since previous Pa
(months)
13.0 (7.6–37.1) 19.2 (14.1–34.7) 0.319
Airway sample bal/sp/cs 1/12/16 0/18/11 0.151
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margin i.e. clinical acceptable difference between the two arms)
of 0.15, power of 80% and alpha of 0.05. For a hypothetical
initial eradication rate of 83% (CC) and 89% (TIS), 34 patients
were needed in each arm (The POWER procedure, Pearson
Chi-square test for two proportions).
Statistical analysis was performed with PASW statistics
18 (SPSS Inc). The proportion of patients with successful
eradication, Pa status and Pa Ab above cut-off were com-
pared for the 2 treatment groups using Fisher's exact test.
Time to recurrence was analyzed by the Kaplan–Meier
method (using log-rank test) using t=0 at the end of treatment
in each group.
Changes from baseline for FEV1% pred, IgG z score, BMI z
score,, IgG z score and Pa antibodies [19] were compared with
the Kruskal–Wallis test.Pa mucoid y/n 2/27 2/27 1.000
Quinolone R y/n 1/28 2/27 1.000
Aminoglycoside R y/n 3/26 2/27 1.000
Azitro maintenance y/n 1/28 2/27 1.000
IgG g/l 8.7 (7.6–11.0) 7.8 (6.9–10.1) 0.168
IgG z score 0.1 (−0.8–0.9) −0.7 (−1.2 to −0.1) 0.051
Pa IgG AU 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.607
Pa IgGN17 AU 0/29 0/29 1.000
Categorical variables are represented as numbers. Continuous variables are
given as median and IQR. PI/PS: pancreatic insufficient/pancreatic sufficient.
R=resistant. AU=arbitrary units. Type of airway sample: bal=broncho
alveolar lavage, sp=sputum, cs=cough swab.3. Results
3.1. Baseline demographic and clinical characteristics
Over the 6 year study period, 109 episodes of new Pa
infection were documented (i.e. on average 18 Pa isolations/
year met the study definition). Sixty one were randomized and
58 completed the study (for patient disposition see Fig. 1). The
main reason for exclusion was the need for IV AB treatment.
First ever Pa infections were seen in 10 (CC) and 8 (TIS)
patients. Pa isolate at study entry had a mucoid phenotype in 2
patients in each arm.
Baseline characteristics were similar between the treatment
groups (Table 1). The youngest child was 1 year of age; 4
children were younger than 2 years.Fig. 1. Flowchart of pDuring the course of the study the percentage of cultures
taken from sputa was 35% in the TIS and 40% in the CC group.
In each group one sample was from BAL.
Time since previous Pa was≤12 months in 22.5% of included
patients (6 out of 19 CC and 3 out of 21 in TOBI group), excluding
patients with their first Pa infection ever (p=0.277).atient disposition.
Fig. 2. Flowchart showing the Pa eradiation success at the end of treatment, relapse rate within 6 months and Pa status according to the Leeds criteria. Black numbers
between brackets concern patients with follow-upb24 months. Therapy for patients with failed eradication at the end of treatment (cross over or IV) is not shown in the
figure (see Results section). Additional therapy was given in the interval of 6 months to 2 years outside the study based on symptoms and eventual recurrence of Pa.
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Pa eradication at end of treatment was similar in both
groups: 23 out of 29 (79.3%) in the TIS group versus 26 out of
29 (89.7%) in the CC group (relative risk 0.88, 95% CI 0.71–
1.11). (Fig. 2). Three patients failed eradication at the end of
therapy in the CC group: 2 were treated with IV antibiotics and
1 was changed to the other treatment arm (i.e. TOBI). Six
patients failed eradication at the end of therapy in the TIS
group: 2 were treated with IV antibiotics followed by CC; 4
were changed to the other treatment arm (i.e. CC). The outcome
of patients with failed eradication is shown in Fig. 2.
Median time to recurrence of Pa positive cultures calculated
at the end of treatment and analyzed by Kaplan Meier survival
was 9 months (95% CI 0.0–19.0) for CC and 5 months (95%Fig. 3. Kaplan Meier survival curve showing the Pa free survival. Median time
to recurrence of any Pa was 9 months (95% CI 0.0–19.0) for CC and 5 months
(95% CI 1.7–8.3) for the T group (Log rank p=0.608).CI 1.7–8.3) for the TIS group (Log rank p=0.608) (Fig. 3).
Nineteen (CC) and 13 (TIS) patients were still Pa free 6 months
after inclusion into the study (see Fig. 2) (p=0.78).
3.3. Pa status at 12 and 24 months
In patients with successful eradication with the study drug,
Pa status at 1 year follow-up was Free off/Intermittent/Chronic
in respectively 13/13/0 patients in the CC and 13/8/1 (p=0.461)
in the TIS group. Three out of 58 patients had chronic Pa
infection after 1 year follow-up. Of the 47 patients with 2 year
follow-up, 5 had developed chronic Pa (10%) (Fig. 2).
Two year follow up data of Pa status were available for 3 of
the 4 patients with mucoid Pa at entry into the study: 1 Chronic
(TIS), 1 Intermittent (TIS) and 1 Free off (CC).
At time of inclusion into the study, 6 of the 58 patients had
detectable anti-pseudomonas antibodies (Pa Ab) level (≥1 and
≤9 AU). One year later, one patient in the CC group developed a
level of Pa Ab levelN17 AU consistent with chronic infection
[19].
3.4. Additional antibiotic treatment because of symptoms from
inclusion until 6 months follow-up
The number of days on additional oral antibiotic treatment
(started for symptoms, not because of failed eradication) was
similar in the TIS and CC groups. There was also no difference in
the number of IV AB courses (14 day combination of tobramycin
and either ceftazidim, meropenem or piperacillin-tazobactam)
given because of symptoms at time of recurrence of Pa infection
(4 CC, 3 TIS) .
3.5. Medication intolerance
One patient was intolerant of TOBI® (severe cough) and
was changed to CC.
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Median change from baseline in FEV1 % after 1 year was
−1% (IQR −9 to 8%) for the whole group (35 patients were
able to perform lung function) and did not differ between the
treatment groups. BMI z score and weight z score did not
change significantly during the 1 year study. Change in median
IgG z score after 1 year did not differ between the treatment
groups (median 0, IQR −0.60 to +0.44).
4. Discussion
To eradicate a new Pa infection in children with CF, oral
ciprofloxacin plus inhaled sodiumcolimesthate for 3 months
was not inferior to 28 days of tobramycin inhalation solution.
Immediate eradication was high and comparable for both
groups (89.7% and 79.3% respectively). Median time to relapse
was similar with both treatment regimens (9 months (95% CI
0.0–19.0) for CC and 5 months (95% CI 1.7–8.3) for the TIS
group). Because Pa genotyping was not performed, our data do
not allow us to differentiate between true re-infection and
recurrence of infection with the same Pa strain.
We acknowledge that there is a profound difference in
treatment intensity between both regimens: 28 days of treatment
with one antibiotic versus 3 months with two antibiotics. The
advantage of TIS is a shorter treatment period with 1 medicine,
possibly leading to better treatment adherence and lesser risk of
drug toxicity. CC as well as TIS are however well established
therapeutic interventions for new Pa infection and therefore it is
important to compare them. Since TIS is not licensed for Pa
eradication, TIS is not reimbursed in this indication in Belgium.
We therefore thought it extra useful to compare both regimens.
Combination therapy with oral ciprofloxacin plus an inhaled
antibiotic during 3 months is still commonly used in CF centers
across Europe [6]. Some centers use a 3 to 4 week treatment
course, especially in asymptomatic patients. Using the prolonged
treatment does not seem to lead to colistin resistance, and even
after use for 15 years only a minimal risk of ciproxin resistance
was reported [16]. The adverse event pattern of quinolones is
similar in adults and children [21]. Because of animal toxicity
data, the concern of damage to the cartilage in growing children
remains. However when specifically monitored in children with
CF, the safety data were reassuring [21]. Close monitoring is
warranted specifically for arthralgia. Also monitoring of drug
resistance and emergence of other pathogens is necessary.
There are only 2 head to head comparisons of different
eradication regimens [8,22]. A very recent study [22] compared a
28 day treatment with oral ciprofloxacin and either inhaled
colistin or tobramycin. Pa was eradicated by 62.8% in the cipro/
colistin arm and by 65.2% in the cirpo/tobramycin arm B (OR
0.90, 95% CI 0.52 to 1.55, p=0.81). In the literature, the success
of eradication and time to relapse after treatment for new Pa vary
widely [4,5,7,9,11–17,23–25]. Differences in treatment sched-
ules, patient populations (age, first or recurrent Pa infection, time
since previous Pa infection), types (BAL, sputum or cough swab)
and frequency of airway culture sampling may explain this
variation in efficacy. When IV treatment followed by CC wasstudied, a 100% Pa eradication was documented with a median
time to recurrence of Pa of 8 months compared to 90%
eradication and a median time to recurrence of Pa of 9 months
in the CC group in our study. In a case series only including
patients with ‘first Pa ever’, median time to recurrence after CC
was 18 months [12]. The first data using TIS for Pa eradication
(28 days versus 56 days) based on follow-up BAL at different
time intervals in patients younger than 6 years showed a lower
proportion of eradication (74%) [14,15] compared to the current
study. When also taking into account oropharyngeal cultures,
eradication success was even lower (around 60%) with only 10 of
21 patients having negative OP cultures within the first 6 months.
A very high (90%) and prolonged eradication (only 35% relapse
after 1 year) was achieved in the ELITE trial for patients
randomized to 56 days as well as to 28 days of TIS [7]. This
study included patients with first Pa ever as well as new Pa after 4
negative sputa over 1 to 2 years, with 60% of patients belonging
to the first category. In our study, only 1 out of 3 treatments
concerned a first Pa infection ever. In the remainder, time since
previous Pa ranged from 7 to 37 months (in 25% of patients with
previousPa isolation it was less than 12 months). This most likely
explains the lower Pa eradication success and higher relapse in
our study compared to the ELITE trial. But our extended
inclusion criteria mimic the real life setting, where eradication
therapy is still attempted for all recurrences of Pa in airway
cultures of patients with CF who are not yet chronically colonized
by Pa.
The final goal of early Pa treatment is to postpone chronic
infection. In our study, only 10% of patients had chronic Pa
infection after a 2 year follow-up based on culture data and only 1
patient showed a Pa antibody titer concordant with chronic
infection. Moreover, 1 year after the eradication treatment, the
FEV1% change from baseline was only −1% (IQR −9 to 8%) and
BMI z score remained stable, thereby confirming a stable clinical
status. Given the variety of interventions after the 6 month time
point, the Pa status at 24 months is likely to be the result of more
than the initial eradication therapy. However the current study
highlights that, in the majority of patients with new Pa isolation,
chronic Pa infection can be postponed for at least 24 months.
This study was underpowered, due to the limited size of our
clinic (N=about 150 children) and the rather high percentage of
children treatedwith IVAB at time of newPa infection. However,
the inclusion rate of eligible patients was high and the 2 groups
were comparable at baseline. In the ELITE study 45 and 43
patients were randomized but the efficacy population concerned
34 and 31 patients only, which is close to the numbers included
and analyzed in our study.
We can conclude that CC and TIS prove effective for
immediate eradication of new Pa lung infection, but with high
relapse rates within 6 months. The high relapse rate is most
likely inherent to the use of the liberal inclusion criteria of
being Pa free for at least 6 months, rather than for 1 or 2 years
as used in other studies [7,8,11]. Also in our cohort however,
chronic Pa colonization was postponed in most children with
CF. Our study thereby confirms that CC continues to be an
effective eradication regimen which is not inferior to 28 days
of TIS.
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